By Francisco Ibanez, Director Clinical Project Management Oncology
This month the International Myeloma Foundation holds its annual Myeloma Action Month to raise awareness of this cancer type. Multiple myeloma (MM) is the second most common blood cancer; however, many patients have never heard of it until they are diagnosed.1
MM is a cancer of the bone marrow plasma cells. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is described as “multiple”, because often there are multiple patches or areas in bone where it grows.2
Here at Mundipharma EDO we have a number of clinical trials ongoing investigating possible future treatments for rare or difficult-to-treat blood cancers, including MM. These treatments are at the very early stages of development, but it is hoped that in the future we may be in a position to bring benefit to patients with MM who currently have very limited treatment options.
Click below to view and download the infographic pdf:
About Multiple Myeloma
- International Myeloma Foundation. March is Myeloma Action Month. http://mam.myeloma.org/ Last accessed 20 March 2019.
- International Myeloma Foundation. What is Multiple Myeloma? http://mam.myeloma.org/educate/ Last accessed 20 March 2019.
- NIH National Cancer Institute. Cancer Stats Facts Myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html Last accessed 20 March 2019.
- Myeloma Patients Europe. Incidence of myeloma. https://www.mpeurope.org/about-myeloma/incidence-of-myeloma/ Last accessed 20 March 2019.
- Myeloma Patients Europe. Treatment of Myeloma https://www.mpeurope.org/about-myeloma/treatment-of-myeloma/ Last accessed 20 March 2019.